The only immunotherapy currently in use in breast cancer treatment are based on antibodies that target proliferation pathways such as HER2 in breast cancers or immunomodulators such as checkpoint inhibitors (CPI) that target TIL in the breast cancer TME. The gene discussed is ERBB2; the disease is breast cancer.